Publications by authors named "Jeffrey A Robl"

Claim this Profile
E
Exploring monocyclic core: Discovery of pyrrol-2-one derivatives as a new series of potent MCHR1 antagonists with in vivo efficacy.
Murugaiah A M Subbaiah, Umasankar Mandal, Vidya Patankar, Selvakumar Bhaskaran, Ravikumar Nutakki, Jeffrey A Robl

Eur J Med Chem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders.
Wei Meng, Robert Brigance, James Mignone, Lidet Negash, Guohua Zhao, Jeffrey A Robl

J Med Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders.
Fang Moore, Wei Wang, Guohua Zhao, James Mignone, Wei Meng, Jeffrey A Robl

Bioorg Med Chem Lett· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities.
Elizabeth A Jurica, Ximao Wu, Kristin N Williams, Lauren E Haque, Richard A Rampulla, Jeffrey A Robl

Bioorg Med Chem· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1-pyrazol-1-yl)methyl)phosphonate (BMS-820132).
Yan Shi, Ying Wang, Wei Meng, Robert P Brigance, Denis E Ryono, Jeffrey A Robl

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.
Huji Turdi, Hannguang Chao, Jon J Hangeland, Saleem Ahmad, Wei Meng, Jeffrey A Robl

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).
Jun Li, Lawrence J Kennedy, Steven J Walker, Haixia Wang, James J Li, Jeffrey A Robl

ACS Med Chem Lett· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.
Jun Shi, Zhengxiang Gu, Elizabeth Anne Jurica, Ximao Wu, Lauren E Haque, Jeffrey A Robl

J Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT Receptor Agonists.
Joseph Carpenter, Ying Wang, Gang Wu, Jianxin Feng, Xiang-Yang Ye, Jeffrey A Robl

J Med Chem· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
Xiang-Yang Ye, Stephanie Y Chen, Shung Wu, David S Yoon, Haixia Wang, Jeffrey A Robl

J Med Chem· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode.
Elizabeth A Jurica, Ximao Wu, Kristin N Williams, Andres S Hernandez, David S Nirschl, Jeffrey A Robl

J Med Chem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor.
Saleem Ahmad, William N Washburn, Andres S Hernandez, Sharon Bisaha, Khehyong Ngu, Jeffrey A Robl

J Med Chem· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies.
Pratik Devasthale, Wei Wang, James Mignone, Kishore Renduchintala, Sridhar Radhakrishnan, Jeffrey A Robl

Bioorg Med Chem Lett· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup.
Pratik Devasthale, Wei Wang, Andres S Hernandez, Fang Moore, Kishore Renduchintala, Jeffrey A Robl

Bioorg Med Chem Lett· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders.
David S Yoon, Shung C Wu, Ramakrishna Seethala, Rajasree Golla, Akbar Nayeem, Jeffrey A Robl

Bioorg Med Chem Lett· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.
William N Washburn, Mark Manfredi, Pratik Devasthale, Guohua Zhao, Saleem Ahmad, Jeffrey A Robl

J Med Chem· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Dean A Wacker, Ying Wang, Matthias Broekema, Karen Rossi, Steven O'Connor, Jeffrey A Robl

J Med Chem· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).
Jun Li, Lawrence J Kennedy, Haixia Wang, James J Li, Steven J Walker, Jeffrey A Robl

ACS Med Chem Lett· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists.
Xiang-Yang Ye, Christian L Morales, Ying Wang, Karen A Rossi, Sarah E Malmstrom, Jeffrey A Robl

Bioorg Med Chem Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Xiang-Yang Ye, David Yoon, Stephanie Y Chen, Akbar Nayeem, Rajasree Golla, Jeffrey A Robl

Bioorg Med Chem Lett· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ mice.
Ricardo A García, Debra J Search, John A Lupisella, Jacek Ostrowski, Bo Guan, Jeffrey A Robl

PLoS One· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.
Guohua Zhao, Chet Kwon, Sharon N Bisaha, Philip D Stein, Karen A Rossi, Jeffrey A Robl

Bioorg Med Chem Lett· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.
John M Fevig, Jianxin Feng, Karen A Rossi, Keith J Miller, Ginger Wu, Jeffrey A Robl

Bioorg Med Chem Lett· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
Yan Shi, Stephen P O'Connor, Doree Sitkoff, Jing Zhang, Mengxiao Shi, Jeffrey A Robl

Bioorg Med Chem Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1).
Shung C Wu, David Yoon, Janice Chin, Katy van Kirk, Ramakrishna Seethala, Jeffrey A Robl

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis